Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash [Canadian Business Journal (Canada)]
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash